Changeflow GovPing Healthcare & Life Sciences Patent Application for Adipocyte Cytotoxic Prot...
Routine Notice Added Draft

Patent Application for Adipocyte Cytotoxic Protein Constructs for Fat Reduction

Email

Summary

Matthew Rein Scholz and Gary Charles Hudson filed US Patent Application 19281400 on July 25, 2025, published April 23, 2026, covering polynucleotide constructs that enable adipocyte-specific production of cytotoxic proteins for reducing adipose tissue volume in visceral, subcutaneous, and abdominal fat deposits. The application also discloses lipid-based delivery vectors for administering these constructs. This is a patent application publication (Kind A1), not a granted patent, and does not yet confer any exclusive rights or compliance obligations on third parties.

“Provided polynucleotide constructs for the adipocyte-specific production of a cytotoxic protein.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 246 changes logged to date.

What changed

The patent application discloses novel polynucleotide constructs engineered for adipocyte-specific cytotoxic protein expression, along with lipid-based delivery vectors, designed to reduce adipose tissue in visceral, subcutaneous, and abdominal regions. The filing represents an early-stage intellectual property claim rather than an approved therapy or approved medical device, and no regulatory approvals or compliance requirements are established by this publication.

Biotechnology firms, pharmaceutical companies, and academic researchers working in metabolic therapeutics or obesity treatment should monitor the prosecution of this application for potential freedom-to-operate considerations. Any party developing competing adipocyte-targeting gene therapies should conduct prior art searches and evaluate potential licensing needs if this application proceeds to grant.

Archived snapshot

Apr 23, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

COMPOSITIONS, SYSTEMS, AND METHODS FOR REDUCING ADIPOSE TISSUE

Application US20260109963A1 Kind: A1 Apr 23, 2026

Inventors

Matthew Rein SCHOLZ, Gary Charles HUDSON

Abstract

Provided polynucleotide constructs for the adipocyte-specific production of a cytotoxic protein. Also provided are formulations and systems, including lipid-based delivery vectors for the delivery of polynucleotide constructs as well as methods for making and using such nucleic acid-based polynucleotide constructs, formulations, and systems for reducing growth and/or survival of adipocytes. Compositions, systems, and methods disclosed herein can be used for reducing adipocytes or adipose volume in visceral, subcutaneous, and abdominal fat.

CPC Classifications

C12N 9/6472 C12N 15/85 C12N 15/88 C12Y 304/22062 A61K 48/00 C12N 2830/008

Filing Date

2025-07-25

Application No.

19281400

View original document →

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Draft
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Investors
Industry sector
3254.1 Biotechnology
Activity scope
Patent application Biotech research Gene therapy development
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare Product Safety

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!